CYNK-001
Showing 1 - 25 of 734
Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma Trial in United States (CYNK-001 systemic and Intra cavity
Recruiting
- Astrocytoma, Grade IV
- +3 more
- CYNK-001 systemic and Intra cavity administration
-
Duarte, California
- +5 more
Jan 20, 2023
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)
Recruiting
- Leukemia
- +19 more
- CYNK-001
-
Denver, Colorado
- +9 more
Sep 9, 2022
Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)
Active, not recruiting
- Multiple Myeloma
- +19 more
- CYNK-001
-
Denver, Colorado
- +8 more
May 24, 2022
Metastatic HER2 Positive Gastroesophageal Junction Cancer Trial in La Jolla, Washington, Hackensack (CYNK-101, Pembrolizumab,
Recruiting
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- CYNK-101
- +6 more
-
La Jolla, California
- +2 more
Jul 12, 2022
Safety, Tolerability, Pharmacokinetics Trial in Karachi (RHN-001 (one tablet 750mg), RHN-001 (750mg * 2 Tablets))
Completed
- Safety
- +2 more
- RHN-001 (one tablet 750mg)
- RHN-001 (750mg * 2 Tablets)
-
Karachi, Sindh, PakistanCenter for Bioequivalence Studies and clinical research (CBSCR),
Apr 26, 2023
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia Trial (HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5%
Not yet recruiting
- Acneiform Eruption Due to Chemical
- +2 more
- HT-001 2% Topical Gel
- +3 more
- (no location specified)
Dec 3, 2022
Advanced Solid Tumor Trial in Shanghai (B4T2-001 autologous CAR-T)
Recruiting
- Advanced Solid Tumor
- B4T2-001 autologous CAR-T
-
Shanghai, China/Shanghai, China
- +1 more
Oct 3, 2023
l Gene Editing Therapy for Cardiovascular Disease
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- +2 more
-
Auckland, New Zealand
- +2 more
Oct 31, 2023
Meibomian Gland Dysfunction, Dry Eye Trial in Australia, Canada, New Zealand (AZR-MD-001 Low Dose, AZR-MD-001 Mid Dose,
Completed
- Meibomian Gland Dysfunction
- Dry Eye
- AZR-MD-001 Low Dose
- +3 more
-
Chatswood, New South Wales, Australia
- +29 more
Nov 23, 2022
Acute Cannabinoid Intoxication Trial in Leiden (ANEB-001, Placebo)
Active, not recruiting
- Acute Cannabinoid Intoxication
- ANEB-001
- Placebo
-
Leiden, ZH, NetherlandsCentre for Human Drug Research (CHDR)
Jan 31, 2023
Cystinosis Trial (Cysteamine Bitartrate, N-Acetylcysteine Amide)
Not yet recruiting
- Cystinosis
- Cysteamine Bitartrate
- N-Acetylcysteine Amide
- (no location specified)
Aug 15, 2023
Vaccine-Preventable Diseases, Herpes Zoster Trial in Seoul, Seongnam-si (CVI-VZV-001, Shingrix)
Recruiting
- Vaccine-Preventable Diseases
- Herpes Zoster
- CVI-VZV-001
- Shingrix
-
Seoul, Eunpyeong-gu, Korea, Republic of
- +1 more
Nov 20, 2023
Atopic Dermatitis Trial in Beijing (GD-iExo-001, normal saline)
Recruiting
- Atopic Dermatitis
- GD-iExo-001
- normal saline
-
Beijing, Beijing, ChinaChinese Academy of Medical Science & Peking Union Medical Colleg
Jul 23, 2023
Pain, Postoperative Trial (Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001)
Recruiting
- Pain, Postoperative
- Ketorolac Tromethamine
- +3 more
-
Pasadena, Maryland
- +5 more
Dec 28, 2022
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +4 more
-
Birmingham, United Kingdom
- +5 more
Sep 18, 2023
Major Depression, Post Traumatic Stress Disorder Trial in Seattle (SM-001)
Not yet recruiting
- Major Depression
- Post Traumatic Stress Disorder
-
Seattle, WashingtonAIMS Institute
Jun 13, 2023
Thyroid Eye Disease Trial (VRDN-001 10 mg/kg Drug:)
Not yet recruiting
- Thyroid Eye Disease
- VRDN-001 10 mg/kg Drug:
- (no location specified)
Sep 7, 2023
Pneumococcal Infections Trial in Adelaide (Gamma-PN3, Pneumovax-23, Prevenar-13)
Recruiting
- Pneumococcal Infections
- Gamma-PN3
- +3 more
-
Adelaide, South Australia, AustraliaUniversity of Adelaide
Aug 1, 2023